Europe

  1. Showing 13 results for:
  2. Europe
All SubjectsResearch and Drug Development

European Patients’ Academy (EUPATI) toolbox

Published by IRDiRC

Research and Drug DevelopmentOrphan DrugPatient InformationToolkit for PatientEUPATIToolboxPatient Training

The EUPATI Academy is the only in-depth training program for patient experts so far in EU that lasts 14months.
It includes an on online training program supported with two weeks of F2F training. The Academy is still operated by EPF, providing high quality training in drug development to patient from EMEA.

View this resource Bookmark this resource

European Patients’ Academy (EUPATI) toolbox

Published by IRDiRC

Research and Drug DevelopmentOrphan DrugPatient InformationToolkit for PatientEUPATIToolboxPatient Training

The EUPATI Academy is the only in-depth training program for patient experts so far in EU that lasts 14months.
It includes an on online training program supported with two weeks of F2F training. The Academy is still operated by EPF, providing high quality training in drug development to patient from EMEA.

View this resource Bookmark this resource

EMA Framework for stakeholder’s engagement – patients, academia, healthcare professionals

Published by IRDiRC

Research and Drug DevelopmentRegulatory AffairsEarly Access SupportScientific AdviceStakeholder EngagementHealthcare Professional

The Agency has been interacting with its stakeholders since its inception. These stakeholder relations have evolved over time and the type and degree of interaction is varied depending on the stakeholder groups and fields of Agency activity.

View this resource Bookmark this resource

European Network of Paediatric Research at the European Medicines Agency

Published by IRDiRC

Research and Drug DevelopmentRegulatory AffairsOrphan DrugEarly Access SupportPaediatric MedicineEuropean Network of Paediatric Research

The European Network of Paediatric Research at the European Medicines Agency (Enpr- EMA) is a network of research networks, investigators and centres with recognised expertise in performing clinical studies in children. Enpr-EMA enables networking and collaboration with members from within and outside the European Union (EU), including academia and the pharmaceutical industry

View this resource Bookmark this resource

European Reference Networks

Published by IRDiRC

Research and Drug DevelopmentNetworkRare DiseaseEuropean Reference NetworkClinical CollaborationResearch Collaboration

Participating in research provides patients with access to cutting-edge treatments and benefit the population and the health services as a whole by leading to the development of more effective, high quality, cost-efficient treatments and healthcare delivery models. ERNs represent an unicum in the clinical and research worldwide collaborative panorama, indeed 24 ERNs span the over 6000 rare diseases by involving 300 EU HCPs and over 1000 specialized units in 25 EU countries

View this resource Bookmark this resource

Mechanism of Coordinated Access to OMPs

Published by IRDiRC

Research and Drug DevelopmentRegulatory AffairsEUnetHTAHTA BodiesReimbursementOrphan MedicineMechanism of Coordinated Access to OMPs

Early dialogue with payers /Medev – MoCA provides a mechanism for European countries to collaborate on coordinated access to orphan medicines in a voluntary, dialogue-based approach, intended to create a fluid set of interactions between key stakeholders, across all aspects of a product

View this resource Bookmark this resource